Gene therapy is a promising approach in the treatment of inherited and common complex disorders of the retina. Preclinical and clinical studies have validated the use of adeno-associated viral vectors (AAV) as a safe and efficient delivery vehicle for gene transfer. Retinal pigment epithelium and rods—and to a lesser extent, cone photoreceptors—can be efficiently targeted with AAV. Other retinal cell types however are more challenging targets. The aim of this study was to characterize the transduction profile and efficiency of in silico designed, synthetic Anc80 AAVs for retinal gene transfer. Three Anc80 variants were evaluated for retinal targeting in mice and primates following subretinal delivery. In the murine retina Anc80L65 demonstrated high level of retinal pigment epithelium and photoreceptor targeting with comparable cone photoreceptor affinity compared to other AAVs. Remarkably, Anc80L65 enhanced transduction kinetics with visible expression as early as day 1 and steady state mRNA levels at day 3. Inner retinal tropism of Anc80 variants demonstrated distinct transduction patterns of Müller glia, retinal ganglion cells and inner nuclear layer neurons. Finally, murine findings with Anc80L65 qualitatively translated to the Rhesus macaque in terms of cell targets, levels and onset of expression. Our findings support the use of Anc80L65 for therapeutic subretinal gene delivery.
Get full access to this article
View all access options for this article.
References
1.
BainbridgeJW, SmithAJ, BarkerSS, et al.Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med, 2008; 358:2231–2239.
2.
MaguireAM, SimonelliF, PierceEA, et al.Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med, 2008; 358:2240–2248.
3.
MaguireAM, HighKA, AuricchioA, et al.Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet, 2009; 374:1597–1605.
4.
CideciyanAV, HauswirthWW, AlemanTS, et al.Human RPE65 gene therapy for Leber congenital amaurosis: Persistence of early visual improvements and safety at 1 year. Hum Gene Ther, 2009; 20:999–1004.
5.
HauswirthWW, AlemanTS, KaushalS, et al.Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. Hum Gen Ther, 2008; 19:979–990.
6.
BainbridgeJW, MehatMS, SundaramV, et al.Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med, 2015; 372:1887–1897.
7.
Le MeurG, LebranchuP, BillaudF, et al.Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 Leber congenital amaurosis. Mol Ther, 2018; 26:256–268.
8.
MacLarenRE, GroppeM, BarnardAR, et al.Retinal gene therapy in patients with choroideremia: Initial findings from a phase 1/2 clinical trial. Lancet, 2014; 383:1129–1137.
9.
GhaziNG, AbboudEB, NowilatySR, et al.Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: Results of a phase I trial. Hum Genet, 2016; 135:327–343.
10.
ConstableIJ, LaiCM, MagnoAL, et al.Gene Therapy in neovascular age-related macular degeneration: Three-year follow-up of a phase 1 randomized dose escalation trial. Am J Ophthalmol, 2017; 177:150–158.
11.
ConstableIJ, PierceCM, LaiCM, et al.Phase 2a randomized clinical trial: Safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine, 2016; 14:168–175.
12.
RakoczyEP, LaiCM, MagnoAL, et al.Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet, 2015; 386:2395–2403.
13.
CarvalhoLS, VandenbergheLH. Promising and delivering gene therapies for vision loss. Vision Res, 2015; 111:124–133.
14.
AliRR, ReichelMB, ThrasherAJ, et al.Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet, 1996; 5:591–594.
15.
TrapaniI, PuppoA, AuricchioA. Vector platforms for gene therapy of inherited retinopathies. Prog Retin Eye Res, 2014; 43:108–128.
16.
PierceEA, BennettJ. The status of RPE65 gene therapy trials: Safety and efficacy. Cold Spring Harb Perspect Med, 2015; 5:a017285.
17.
ColellaP, AuricchioA. Gene therapy of inherited retinopathies: A long and successful road from viral vectors to patients. Hum Gene Ther, 2012; 23:796–807.
18.
BuchPK, BainbridgeJW,& AliRR. AAV-mediated gene therapy for retinal disorders: From mouse to man. Gene Ther, 2008; 15:849–857.
19.
BoyeSE, BoyeSL, LewinAS, et al.A comprehensive review of retinal gene therapy. Mol Ther, 2013; 21:509–519.
20.
SchonC, BielM, MichalakisS. Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications. Eur J Pharm Biopharm, 2015; 95:343–352.
LebherzC, MaguireA, TangW, et al.Novel AAV serotypes for improved ocular gene transfer. J Gen Med, 2008; 10:375–382.
24.
NatkunarajahM, TrittibachP, McIntoshJ, et al.Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene Ther, 2008; 15:463–467.
25.
ByrneLC, OzturkBE, LeeT, et al.Retinoschisin gene therapy in photoreceptors, Muller glia or all retinal cells in the Rs1h-/- mouse. Gene Ther, 2014; 6:585–92
26.
DalkaraD, ByrneLC, KlimczakRR, et al.In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med, 2013; 5:189ra176.
27.
DalkaraD, KolstadKD, CaporaleN, et al.Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther, 2009; 17:2096–2102.
28.
KlimczakRR, KoerberJT, DalkaraD, et al.A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Muller cells. PLoS One, 2009; 4:e7467.
29.
YinL, GreenbergK, HunterJJ, et al.Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci, 2011; 52:2775–2783.
30.
GioveTJ, Sena-EstevesM, EldredWD. Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection. Exp Eye Res, 2010; 91:652–659.
31.
CroninT, VandenbergheLH, HantzP, et al.Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. EMBO Mol Med, 2014; 6:1175–1190.
32.
ScalabrinoML, BoyeSL, FransenKM, et al.Intravitreal delivery of a novel AAV vector targets ON bipolar cells and restores visual function in a mouse model of complete congenital stationary night blindness. Hum Mol Genet, 2015; 24:6229–6239.
33.
CarvalhoLS, XuJ, PearsonRA, et al.Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet, 2011; 20:3161–3175.
34.
MihelecM, PearsonRA, RobbieSJ, et al.Long-term preservation of cones and improvement in visual function following gene therapy in a mouse model of leber congenital amaurosis caused by guanylate cyclase-1 deficiency. Hum Gen Ther, 2011; 22:1179–1190.
35.
BoyeSL, ConlonT, ErgerK, et al.Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest Ophthalmol Vis Sci, 2011; 52:7098–7108.
36.
BoyeSL, PeshenkoIV, HuangWC, et al.AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. Hum Gene Ther, 2013; 24:189–202.
37.
BoyeSE, BoyeSL, PangJ, et al.Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. PLoS One, 2010; 5:e11306.
38.
YeGJ, KomaromyAM, ZeissCJ, et al.Safety and Efficacy of AAV5 Vectors Expressing Human or Canine CNGB3 in CNGB3-mutant Dogs. Hum Gene Ther Clin Dev, 2017; 28:197–207.
39.
MowatFM, OccelliLM, BartoeJT, et al.Gene therapy in a large animal model of PDE6A-retinitis pigmentosa. Front Neurosci, 2017; 11:342.
40.
ZhangY, DengWT, DuW, et al.Gene-based therapy in a mouse model of blue cone monochromacy. Sci Rep, 2017; 7:6690.
41.
GootwineE, Abu-SiamM, ObolenskyA, et al.Gene augmentation therapy for a missense substitution in the cGMP-binding domain of ovine CNGA3 gene restores vision in day-blind sheep. Invest Ophthalmol Vis Sci, 2017; 58:1577–1584.
42.
GootwineE, OfriR, BaninE, et al.Safety and efficacy evaluation of rAAV2tYF-PR1.7-hCNGA3 vector delivered by subretinal injection in CNGA3 mutant achromatopsia sheep. Hum Gene Ther Clin Dev, 2017; 28:96–107.
43.
YeGJ, BudzynskiE, SonnentagP, et al.Safety and biodistribution evaluation in CNGB3-deficient mice of rAAV2tYF-PR1.7-hCNGB3, a recombinant AAV vector for treatment of achromatopsia. Hum Gene Ther Clin Dev, 2016; Mar7. [Epub ahead of print].
44.
BaninE, GootwineE, ObolenskyA, et al.Gene Augmentation Therapy Restores Retinal Function and Visual Behavior in a Sheep Model of CNGA3 Achromatopsia. Mol Ther, 2015; 23:1423–1433.
45.
LheriteauE, PetitL, WeberM, et al.Successful gene therapy in the RPGRIP1-deficient dog: A large model of cone-rod dystrophy. Mol Ther, 2014; 22:265–277.
46.
MichalakisS, MuhlfriedelR, TanimotoN, et al.Gene therapy restores missing cone-mediated vision in the CNGA3-/- mouse model of achromatopsia. Adv Exp Med Biol, 2012; 723:183–189.
47.
PangJJ, DengWT, DaiX, et al.AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS One, 2012; 7:e35250.
48.
LoteryAJ, YangGS, MullinsRF, et al.Adeno-associated virus type 5: Transduction efficiency and cell-type specificity in the primate retina. Hum Gene Ther, 2003; 14:1663–1671.
49.
VandenbergheLH, BellP, MaguireAM, et al.Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med, 2011; 3:88ra54.
50.
VandenbergheLH, BellP, MaguireAM, et al.AAV9 targets cone photoreceptors in the nonhuman primate retina. PLoS One, 2013; 8:e53463.
51.
HickeyDG, EdwardsTL, BarnardAR, et al.Tropism of engineered and evolved recombinant AAV serotypes in the rd1 mouse and ex vivo primate retina. Gene Ther, 2017; 24:787–800.
52.
RamachandranPS, LeeV, WeiZ, et al.Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina. Hum Gene Ther, 2017; 28: 154–167.
53.
MancusoK, HendricksonAE, ConnorTBJr. et al. Recombinant adeno-associated virus targets passenger gene expression to cones in primate retina. J Opt Soc Am A Opt Image Sci Vis, 2007; 24:1411–1416.
54.
BoyeSE, AlexanderJJ, BoyeSL, et al.The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Hum Gene Ther, 2012; 23:1101–1115.
55.
ZinnE, PacouretS, KhaychukV, et al.In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep, 2015; 12:1056–1068.
56.
LockM, AlviraM, VandenbergheLH, et al.Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther, 2010; 21:1259–1271.
57.
SchwedeT, KoppJ, GuexN, et al.SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res, 2003; 31:3381–3385.
58.
PettersenEF, GoddardTD, HuangCC, et al.UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem, 2004; 25:1605–1612.
59.
DolinskyTJ, NielsenJE, McCammonJA, et al.PDB2PQR: An automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res, 2004; 32:W665–667.
60.
RostkowskiM, OlssonMH, SondergaardCR, et al.Graphical analysis of pH-dependent properties of proteins predicted using PROPKA. BMC Struct Biol, 2011; 11:6.
61.
BakerNA, SeptD, JosephS, et al.Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc Natl Acad Sci U S A, 2001; 98:10037–10041.
62.
KonecnyR, TrylskaJ, TamaF, et al.Electrostatic properties of cowpea chlorotic mottle virus and cucumber mosaic virus capsids. Biopolymers, 2006; 82:106–120.
BainbridgeJW, AliRR. Success in sight: The eyes have it! Ocular gene therapy trials for LCA look promising. Gen Ther, 2008; 15:1191–1192.
65.
AuricchioA, SmithAJ, AliRR. The future looks brighter after 25 years of retinal gene therapy. Hum Gene Ther, 2017; 28:982–987.
66.
ZinnE, VandenbergheLH. Adeno-associated virus: Fit to serve. Curr Opin Virol, 2014; 8:90–97.
67.
BuningH, HuberA, ZhangL, et al.Engineering the AAV capsid to optimize vector-host-interactions. Curr Opin Pharmacol, 2015; 24:94–104.
68.
VandenbergheLH, WilsonJM, GaoG. Tailoring the AAV vector capsid for gene therapy. Gene Ther, 2009; 16:311–319.
69.
MancusoK, HauswirthWW, LiQ, et al.Gene therapy for red-green colour blindness in adult primates. Nature, 2009; 461:784–787.
70.
YeGJ, BudzynskiE, SonnentagP, et al.Safety and biodistribution evaluation in cynomolgus macaques of rAAV2tYF-PR1.7-hCNGB3, a recombinant AAV vector for treatment of achromatopsia. Hum Gene Ther Clin Dev, 2016; 27:37–48.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
